美国 - 英文 - NLM (National Library of Medicine)

redpharm drug, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high

美国 - 英文 - NLM (National Library of Medicine)

greenstone llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated for treatment of nyha class iii–iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone is usually administered in conjunction with other heart failure therapies. spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure

美国 - 英文 - NLM (National Library of Medicine)

sandoz inc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. aldosterone levels may be exceptionally high in this condition. spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. for nephrotic patients when treatm

美国 - 英文 - NLM (National Library of Medicine)

american health packaging - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. sp

美国 - 英文 - NLM (National Library of Medicine)

remedyrepack inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 100 mg - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. spironolactone tablets are indicated for the management of edema in the following settings: - cirrhosis of the liver when edema is not responsive to fluid and sodium restriction. - nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. because it increases serum potassium, spironolactone tablets may be useful for treating edema when administration of other diuretics has caused hypokalemia. spironolactone tablets are indicated in the following settings: - short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). spironolactone tablets are contraindicated in the patients with: - hyperkalemia - addison’s disease - concomitant use of eplerenone risk summary based on mechanism of action and findings in animal studies, spironolactone may affect sex differentiation of the male during embryogenesis (see data) . rat embryofetal studies report feminization of male fetuses and endocrine dysfunction in females exposed to spironolactone in utero. limited available data from published case reports and case series did not demonstrate an association of major malformations or other adverse pregnancy outcomes with spironolactone . there are risks to the mother and fetus associated with heart failure, cirrhosis and poorly controlled hypertension during pregnancy ( see clinical considerations) . because of the potential risk to the male fetus due to anti-androgenic properties of spironolactone and animal data, avoid spironolactone in pregnant women or advise a pregnant woman of the potential risk to a male fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnant women with congestive heart failure are at increased risk for preterm birth. stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. clinical classification of heart disease may worsen with pregnancy and lead to maternal death. closely monitor pregnant patients for destabilization of their heart failure. pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, preterm delivery, fetal growth restriction and maternal death. outcomes are worse with coexisting esophageal varices. pregnant women with cirrhosis of the liver should be carefully monitored and managed accordingly. hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. data animal data teratology studies with spironolactone tablets have been carried out in mice and rabbits at doses of up to 20 mg/kg/day. on a body surface area basis, this dose in the mouse is substantially below the maximum recommended human dose and, in the rabbit, approximates the maximum recommended human dose. no teratogenic or other embryotoxic effects were observed in mice, but the 20 mg/kg dose caused an increased rate of resorption and a lower number of live fetuses in rabbits. because of its antiandrogenic activity and the requirement of testosterone for male morphogenesis, spironolactone tablets may have the potential for adversely affecting sex differentiation of the male during embryogenesis. when administered to rats at 200 mg/kg/day between gestation days 13 and 21 (late embryogenesis and fetal development), feminization of male fetuses was observed. offspring exposed during late pregnancy to 50 and 100 mg/kg/day doses of spironolactone tablets exhibited changes in the reproductive tract including dose-dependent decreases in weights of the ventral prostate and seminal vesicle in males, ovaries and uteri that were enlarged in females, and other indications of endocrine dysfunction, that persisted into adulthood. spironolactone tablets has known endocrine effects in animals including progestational and antiandrogenic effects. risk summary spironolactone is not present in breastmilk; however, limited data from a lactating woman at 17 days postpartum reports the presence of the active metabolite, canrenone, in human breast milk in low amounts that are expected to be clinically inconsequential. in this case, there were no adverse effects reported for the breastfed infant after short term exposure to spironolactone; however, long term effects on a breastfed infant are unknown. there are no data on spironolactone effects on milk production. consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for spironolactone and any potential adverse effects on the breastfed child from spironolactone or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. spironolactone tablets are substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, monitor renal function. spironolactone tablets are substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. patients with renal impairment are at increased risk of hyperkalemia. monitor potassium closely. spironolactone tablets can cause sudden alterations of fluid and electrolyte balance which may precipitate impaired neurological function, worsening hepatic encephalopathy and coma in patients with hepatic disease with cirrhosis and ascites. in these patients, initiate spironolactone tablets in the hospital [ see dosage and administration (2.4) and clinical pharmacology (12.3)] . clearance of spironolactone and its metabolites is reduced in patients with cirrhosis. in patients with cirrhosis, start with lowest initial dose and titrate slowly [ see dosage and administration (2.4) and clinical pharmacology (12.3)] .

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - spironolactone, quantity: 25 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; peppermint oil; purified talc; sodium starch glycollate; lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; polysorbate 80; sunset yellow fcf aluminium lake; erythrosine aluminium lake; maize starch - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver and nephrotic syndrome; diagnosis and treatment of primary aldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate; hirsutism. essential hypertension. spironolactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. spironolactone improves the hypotensive action of thiazide diuretics, while at the same time reducing or preventing potassium loss due to the thiazide. spironolactone enhances the effectiveness of other antihypertensive agents such as beta-blockers, vasodilators, etc. congestive cardiac failure. when used alone, spironolactone is effective in the management of oedema and sodium retention associated with congestive cardiac failure. spironolactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics, spironolactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics, spironolactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalised patients, since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema. when used alone, spironolactone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. it provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics, thus avoiding possible precipitation of hepatic coma. nephrotic syndrome. although glucocorticoids, whose anti-inflammatory activity appears to benefit the primary pathological process in the renal glomerulus, should probably be employed first, spironolactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism. spironolactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. spironolactone may also be used for the short-term preoperative treatment of patients with primary hyperaldosteronism, long-term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females. spironolactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of spiractin should be considered only after all other alternatives of non-drug therapy have been explored. for women of childbearing age, see contraindications and use in pregnancy.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

australian naturalcare products pty ltd - ascorbic acid,betacarotene,cyanocobalamin,folic acid,iron (ii) glycinate,pyridoxine hydrochloride,riboflavin,thiamine hydrochloride -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - mecobalamin, quantity: 400 microgram; riboflavine sodium phosphate, quantity: 20 mg; iron (ii) glycinate, quantity: 120 mg (equivalent: iron, qty 24 mg); calcium ascorbate dihydrate, quantity: 242 mg (equivalent: ascorbic acid, qty 200 mg); pyridoxal 5-phosphate monohydrate, quantity: 20 mg (equivalent: pyridoxine, qty 12.8 mg); levomefolate calcium, quantity: 433 microgram (equivalent: levomefolic acid, qty 400 microgram); thiamine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; hypromellose; citric acid; microcrystalline cellulose; silicon dioxide; maltodextrin; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - helps convert (state food) into energy ; maintain/support energy production ; maintain/support general health and wellbeing ; aid/assist healthy red blood cell production ; maintain/support red blood cell health ; maintain/support blood health ; helps maintain/support transport of oxygen in the body ; aid/assist/helps oxygen transport to body tissues ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support (state vitamin/mineral) within normal range

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

swisse wellness pty ltd - pyridoxine hydrochloride, quantity: 2.43 mg (equivalent: pyridoxine, qty 2 mg); cyanocobalamin, quantity: 1 microgram; calcium ascorbate dihydrate, quantity: 21.67 mg (equivalent: ascorbic acid, qty 17.9 mg); iron (ii) glycinate, quantity: 74 mg (equivalent: iron, qty 20 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate dihydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; spearmint oil; carnauba wax; hypromellose; citric acid; maltodextrin; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - helps maintain healthy blood with vitamin c to assist iron absorption

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

swisse wellness pty ltd - iron (ii) glycinate, quantity: 70.3 mg (equivalent: iron, qty 19 mg); pyridoxine hydrochloride, quantity: 2.31 mg (equivalent: pyridoxine, qty 1.9 mg); cyanocobalamin, quantity: 1 microgram; calcium ascorbate dihydrate, quantity: 36.31 mg (equivalent: ascorbic acid, qty 30 mg) - tablet, film coated - excipient ingredients: maltodextrin; magnesium stearate; crospovidone; carnauba wax; calcium hydrogen phosphate dihydrate; hypromellose; croscarmellose sodium; colloidal anhydrous silica; spearmint oil; silicon dioxide; microcrystalline cellulose; citric acid; polysorbate 80; purified talc; polyvinyl alcohol; macrogol 3350; titanium dioxide; iron oxide yellow; iron oxide red; iron oxide black - maintain/support energy production ; maintain/support vitality ; relieve weariness/tiredness/fatigue/feeling of weakness ; aid/assist healthy red blood cell production ; maintain/support blood health ; helps maintain/support transport of oxygen in the body ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency